Welcome to our dedicated page for Impact Biomedical news (Ticker: IBO), a resource for investors and traders seeking the latest updates and insights on Impact Biomedical stock.
Impact BioMedical Inc. develops and patents healthcare technologies for biopharmaceutical, consumer health and wellness applications. News about IBO centers on intellectual-property milestones, technology platforms such as 3F™, Linebacker™ and Equivir™, and partner-based paths for research, licensing, co-development and commercialization.
Company updates also cover portfolio activity in infectious-disease control, inflammatory disease, oncology evaluation and air purification technology, along with capital-structure actions, shareholder communications, market-action statements, governance matters and financial-reporting disclosures such as going-concern audit language.
Impact BioMedical Inc. (NYSE American: IBO) has unveiled its executive leadership team to spearhead the company's next phase of innovation and growth. The team includes:
Frank D. Heuszel as CEO, bringing experience in executive leadership, finance, and strategic planning. He previously served as CEO of DSS, Inc. and has a background in commercial banking.
Mark Suseck as COO, with experience in public and private healthcare companies. He previously served as COO of DSS BioHealth Holdings Inc. and CEO of Vivacitas Oncology Inc.
Todd Macko as CFO, also serving as CFO of DSS Inc. He brings over 25 years of public and corporate fiscal management experience.
The leadership team aims to advance Impact BioMedical's mission of discovering, developing, and patenting unique healthcare solutions.
Impact BioMedical Inc. (NYSE American: IBO) has successfully closed its initial public offering of 1,500,000 common stock shares at $3.00 per share. Trading began on the NYSE American Market on September 16, 2024, under the ticker symbol 'IBO'. The company granted underwriters a 45-day option to purchase up to 225,000 additional shares. Revere Securities, served as the sole book-running manager and received warrants to purchase up to 75,000 shares (86,250 if over-allotment is fully exercised) at $3.75 per share. The warrants are exercisable from nine months after the offering's commencement until the third anniversary. The SEC declared the registration statement effective on September 13, 2024.
Impact BioMedical Inc. (NYSE American: IBO), a company focused on human healthcare and wellness, has announced the pricing of its initial public offering. The company is offering 1,500,000 shares of common stock at $3.00 per share. Trading is expected to begin on the NYSE American Market on September 16, 2024, under the ticker symbol 'IBO'. The offering is set to close on September 17, 2024, subject to customary conditions. Impact has also granted underwriters a 45-day option to purchase an additional 225,000 shares. Revere Securities, is the book-running manager for the offering. The company has agreed to issue underwriter warrants to purchase up to 75,000 shares (86,250 if over-allotment is exercised), exercisable at 125% of the IPO price.